A Guide to De-escalation of Combination Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study
Patient adherence and the number of prior failed biologic therapies were identified as potential risk factors for re-escalation. The type of agent being de-escalated (biologic or Janus kinase inhibitors [JAKi] did not correlate with the need for re-escalation).
Authors
- Kerri Glassner (ORCID: https://orcid.org/0000-0002-5059-0470)
- Adam Saleh (ORCID: https://orcid.org/0000-0002-1410-237X)
- Bincy Abraham (ORCID: https://orcid.org/0000-0003-0308-1224)
- Rajdeepsingh Waghela
- Joshua Moskow
- Mohamad Irani (ORCID: https://orcid.org/0000-0002-8469-4796)
- Christopher Fan (ORCID: https://orcid.org/0000-0002-7117-6885)
- Shayan Amini
Institutions
- Houston Methodist (US)
- Methodist Hospital (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Crohn s & Colitis 360
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1093/crocol/otaf026
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82